Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:March 2008

Use our guide to learn which trials are right for you!

A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-Type Specific Expanded Cohorts at the Recommended Phase 2 Dose (Renal Cell Carcinoma and Non-Small Cell Lung Carcinoma)

The main purpose of this study is to:

- Evaluate the safety of vorinostat in combination with sorafenib.

- Determine the largest dose of vorinostat + sorafenib that can be given safely to

- Determine if vorinostat + sorafenib are effective in stopping tumors from growing or in
decreasing their size.

- Study the side effects of vorinostat + sorafenib.

Eligibility criteria include but are not limited to:

- 18 years or older with advanced solid tumor(s),

- Renal cell or non-small cell lung cancer.
We found this trial at
13001 E. 17th Pl.
Aurora, Colorado 80045
University of Colorado Cancer Center - Anschutz Cancer Pavilion The University of Colorado Denver |...
Aurora, CO
Click here to add this to my saved trials